there was a report on Channel 10 news recently regards a first in Australia of endovascular repair of the Mitral valve in RPA . Anteris has a new such device under development. I believe the company does not wish to elaborate much at this stage before the tech is secured by patents. This area will grow to rival AVR. If the company was to sell the AVR tech to a major they could retain this mitral tech in the company and investors may not have to pay capital gain immediately. The MVR tech is very valuable and could earn many extra dollars for a complete sale IMHO. No advice.
there was a report on Channel 10 news recently regards a first...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.22 |
Change
0.740(6.45%) |
Mkt cap ! $258.3M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $12.25 | $11.49 | $395.2K | 33.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $11.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.22 | 127 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |